DSGNDesign Therapeutics, Inc.
$11.49+77% 1Y
$11.49
$5.5352 weeks$15.94
Price
+77%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 5% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for DSGN today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$717.6M
1 year+77%
5 years-22%
Charts
As reported to the SEC, without any scoring.
Design Therapeutics, Inc. (DSGN) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $20M. For the full year FY2025, revenue was $0 and net income −$70M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results.Earnings release · press release
- May 18, 2026On May 18, 2026, Design Therapeutics, Inc. (the “Company”) announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (“FA”)Other event · Form 8-K
- Apr 28, 2026Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.